

Practitioner's Docket No. MWH-0029US

09/856803#7/A
531 R&D PCT
25 MAY 2001
PATENT
A.Q.
11-13-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ligget, Stephen B.

Application No.: To be assigned
Filed: May 25, 2001

Group No.: To be assigned
Examiner: To be assigned

For: POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE BETA2-ADRENERGIC
RECEPTOR

Assistant Commissioner for Patents
Washington, D.C. 20231

FIRST PRELIMINARY AMENDMENT TO CLAIMS
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is the National Phase filing of PCT/US99/27963. This paper is filed to cancel claims. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.

IN THE CLAIMS


Please cancel claims 22, 24, and 25 without prejudice or disclaimer.

REMARKS

This amendment cancels claims in order to facilitate prosecution of the application. Should any questions arise, or if Applicant or Applicant's Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.

Respectfully submitted,

Reg. No. 47,562
Tel. No. 203-786-3473


Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

09856803-0524504